Therefore, HSPC LV-fVIII gene therapy appears to be a promising approach with lifelong curative potential that can be accessible to all patients with hemophilia without age restriction, as both HSPC transplantation and HSPC gene therapy have been successfully utilized in children <1 year of age for other disease indications. Here, F8 is linked to hemophilia.